Medpace Holdings (MEDP) AI Stock Analysis

• Market Cap: $12.89B
• Dividend Yield: N/A
• Average Volume (3M): 617.72K
• Price to Earnings (P/E): 34.1
• Beta (1Y): 1.18
• Revenue Growth: 9.94%
• EPS Growth: 25.30%
• Country: US
• Employees: 5,900
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.10
• Shares Outstanding: 28,093,025
• 10 Day Avg. Volume: 407,110
• 30 Day Avg. Volume: 617,717
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 4.14
• Enterprise Value/Gross Profit: 13.11
• Enterprise Value/Ebitda: 18.85
• 1Y Price Target: $421.22
• Price Target Upside: -8.16% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 10

• Rating: 78 Outperform
• Price Target: $499.00 ▲(8.80% Upside)

Medpace Holdings demonstrates strong financial performance and a positive earnings outlook, supported by robust revenue growth and profitability. Technical indicators suggest bullish momentum, though the stock is potentially overbought. Valuation is fair, albeit with no dividend yield to attract income investors. Uncertainties around sustainable growth are a consideration.

Positive Factors

Business Outlook

Management noted a continuation of strong RFP activity and a meaningful reduction in cancellations, indicating a more upbeat outlook.

Quarterly Performance

MEDP's strong quarterly performance exceeded low expectations, which contributed to a significant stock price increase.

Revenue Growth

Lower levels of cancellations and higher request for proposal activities are promising factors for future revenue growth.

Negative Factors

Market Expectations

The move has overshot the mark, as current share prices are back to peak multiples from last year without the same expected EPS acceleration.

Stock Downgrade

The stock has been downgraded to Sell from Hold, as the recent 55% move is believed to reflect short covering rather than a material change in fundamentals.

Stock Valuation

Shares are considered overvalued at 31 times the revised estimates relative to expected growth.

Medpace Holdings Business Overview & Revenue Model

Company Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

How the Company Makes Money

Medpace generates revenue primarily through its clinical research services, which include the design, management, and execution of clinical trials for clients in the pharmaceutical and biotech sectors. The company's revenue model is largely fee-for-service, where it charges clients based on the scope and complexity of the services provided, often structured around milestones in the clinical trial process. Key revenue streams include clinical trial management services, laboratory services, and regulatory consulting. Additionally, Medpace has established significant partnerships with leading pharmaceutical companies, which contribute to its earnings by providing a steady stream of projects and enhancing its reputation in the market. The company's focus on specific therapeutic areas allows it to command higher fees due to its specialized knowledge and expertise.

Medpace Holdings Financial Statement Overview

Summary

Medpace Holdings shows robust financial health with strong revenue and profit growth. The company maintains solid cash flow generation, supporting its operational and strategic initiatives. However, the declining equity ratio and high liabilities warrant careful monitoring.

Income Statement

The company exhibits strong revenue growth, with a notable increase from $925.93M in 2020 to $2.23B in TTM 2025. Gross profit margin has consistently improved, reaching 31.6% in TTM 2025. The net profit margin also shows a healthy trend, rising to 18.7% in TTM 2025. EBIT and EBITDA margins are strong at 21.4% and 22.0% respectively, indicating efficient operations. The company benefits from robust profitability metrics, though rising competition in the industry could pose future challenges.

Balance Sheet

The debt-to-equity ratio has fluctuated but remains manageable at 0.72 in TTM 2025. The equity ratio has declined from 57.4% in 2020 to 11.0% in TTM 2025, indicating a reduction in equity as a proportion of total assets. Return on equity has improved significantly, reaching 242.7% in TTM 2025, reflecting strong profitability. The balance sheet shows a high level of liabilities relative to equity, which could be a risk if cash flows are constrained.

Cash Flow

Operating cash flow has grown steadily, with a strong TTM 2025 figure of $614.10M. Free cash flow growth is positive, with a notable increase from $227.34M in 2020 to $595.92M in TTM 2025. The operating cash flow to net income ratio is 1.47, indicating efficient conversion of income into cash. Free cash flow to net income remains strong at 1.42, showcasing the company's ability to generate cash relative to earnings. Cash flows are solid, although high financing cash outflows could impact future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.23B	2.11B	1.89B	1.46B	1.14B	925.92M
Gross Profit	705.69M	656.30M	524.50M	432.44M	328.15M	278.73M
EBITDA	490.74M	476.12M	363.15M	301.04M	219.73M	186.57M
Net Income	418.30M	404.39M	282.81M	245.37M	181.85M	145.38M
Balance Sheet
Total Assets	1.57B	2.10B	1.66B	1.35B	1.66B	1.39B
Cash, Cash Equivalents and Short-Term Investments	46.33M	669.44M	245.45M	28.27M	461.30M	277.77M
Total Debt	124.95M	149.52M	142.12M	188.87M	130.97M	115.14M
Total Liabilities	1.40B	1.28B	1.10B	966.11M	707.01M	584.90M
Stockholders Equity	172.35M	825.54M	558.95M	386.39M	952.93M	805.78M
Cash Flow
Free Cash Flow	579.82M	572.27M	396.73M	351.17M	235.06M	227.34M
Operating Cash Flow	614.10M	608.82M	433.37M	388.05M	263.33M	258.68M
Investing Cash Flow	-34.05M	-28.31M	-34.63M	-38.74M	-31.36M	-31.21M
Financing Cash Flow	-1.05B	-154.01M	-182.64M	-775.77M	-44.45M	-82.28M

Medpace Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 458.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MEDP, the sentiment is Positive. The current price of 458.66 is above the 20-day moving average (MA) of 431.30, above the 50-day MA of 359.30, and above the 200-day MA of 334.16, indicating a bullish trend. The MACD of 28.81 indicates Positive momentum. The RSI at 66.53 is Neutral, neither overbought nor oversold. The STOCH value of 90.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MEDP.

Medpace Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	78 Outperform	$12.89B	34.11	89.38%	―	9.94%	25.30%
IDXX	77 Outperform	$52.32B	54.43	64.87%	―	6.68%	18.84%
ICLR	77 Outperform	$13.64B	18.02	8.30%	―	-2.91%	12.92%
RVTY	63 Neutral	$10.21B	37.34	3.61%	0.31%	3.33%	32.86%
Sector *	57 Neutral	£5.17B	4.93	-44.55%	2.32%	28.89%	-10.08%
CRL	51 Neutral	$7.52B	449.94	-1.96%	―	-1.21%	-115.44%

Medpace Holdings Corporate Events

Medpace Holdings Amends Credit Facility with PNC Bank

On July 17, 2025, Medpace Holdings, Inc. announced an amendment to its unsecured credit facility with PNC Bank, increasing the line of credit to $10 million. For the second quarter of 2025, Medpace reported a 14.2% increase in revenue to $603.3 million and a 16.2% rise in EBITDA to $130.5 million compared to the previous year. The company also repurchased shares worth $518.5 million during the quarter. Despite a slight decrease in backlog, Medpace’s financial results reflect strong growth and operational efficiency, positioning it well within the industry.

The most recent analyst rating on (MEDP) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.

Medpace Holdings Approves Key Proposals at Annual Meeting

On May 16, 2025, Medpace Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were approved. The stockholders approved the 2016 Amended and Restated Incentive Award Plan, which extended the expiration date to February 6, 2035, without increasing the number of shares for issuance. Additionally, the election of Class III Directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and the advisory vote on executive compensation were all approved. A non-binding advisory stockholder proposal regarding simple majority voting was also passed.

The most recent analyst rating on (MEDP) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.